hugbu schreef op 7 december 2011 19:18:
Toch iets gevonden in de VS : ('k heb de gekende uitleg er even tussenuit geknipt)
Galapagos RA drug catches eye of investors World News | November 28, 2011
Kevin Grogan
Mid-stage data on a
little-known drug from Galapagos for rheumatoid arthritis has
caused a stir.
Last week, the Belgian drugmaker released data from a Phase II study of GLPG0634, which showed that the Janus kinase (JAK)-1 inhibitor achieved the primary endpoint of significant improvement in the signs and symptoms of RA. The 36-patient trial lasted for four weeks and 83% of patients showed improvement in ACR20 levels at just four weeks.
............................................
In terms of partnering, Edison says it appears that
Galapagos "may have had an option-based offer on the table, but it probably makes more sense to retain rights and conduct further studies".